5 Most Oversold AI Stocks to Buy According to Analysts

3. Stereotaxis, Inc. (NYSEAMERICAN:STXS)

Trading with an implied upside of 124.7% and an RSI of 39.6, Stereotaxis, Inc. (NYSEAMERICAN:STXS) has emerged as a notable oversold play in the AI sector.

However, more recently, Piper Sandler lowered its price target on Stereotaxis, Inc. (NYSEAMERICAN:STXS) to $3.5 from $4.0 on May 13, 2026, while keeping an “Overweight” rating. The firm pointed to headwinds in the company’s disposables business as Stereotaxis winds down its relationship with Johnson & Johnson and continues to face supply constraints with MAGiC catheter production. At the same time, the firm cited management’s confidence in its goal to ramp up production by the end of 2026.

That caution followed Stereotaxis, Inc. (NYSEAMERICAN:STXS)’s first-quarter update the previous day, where the company reported revenue of $6.3 million, down from $7.5 million in the prior-year period. System revenue came in at $1.3 million, while recurring revenue was $5.0 million, compared with $2.0 million and $5.5 million, respectively, a year earlier. The company said recurring revenue was pressured by the transition away from legacy J&J catheters, with still modest contributions from its new proprietary catheters.

At the same time, Stereotaxis, Inc. (NYSEAMERICAN:STXS) continued to point to regulatory and product progress across its newer platform.

Its robotically navigated MAGiC catheter received U.S. FDA approval in January and is now being used at multiple sites in the U.S. and Europe. The Synchrony digital operating room system also received FDA clearance in April, with initial orders and shipments underway.

Looking ahead, production remains central to the company’s 2026 growth plans.

Stereotaxis, Inc. (NYSEAMERICAN:STXS) said demand for MAGiC exceeds supply, and manufacturing continues to progress toward an expected 500 catheters per month by year-end. The company also expects annual revenue to surpass $40 million in 2026, with revenue in both Q3 and Q4 expected to exceed $10 million.

Stereotaxis, Inc. (NYSEAMERICAN:STXS) designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory. Its primary products are the Genesis RMN System, the Odyssey Solution, and other related devices.